Clinical Significance of IgG4 Serum Concentration in Graves' Disease
- PMID: 39032009
- DOI: 10.2478/aite-2024-0015
Clinical Significance of IgG4 Serum Concentration in Graves' Disease
Abstract
Elevated immunoglobulin G4 (IgG4) serum antibodies are an important feature of IgG4-related disease. However, IgG4 antibodies can play a role in autoimmune thyroid disorders. In this study, we aimed to evaluate the impact of serum IgG4 levels on clinical features of Graves' disease (GD). We recruited 60 patients with GD (48 patients without thyroid eye disease, 12 patients with moderate-to-severe Graves' orbitopathy [GO], and 25 healthy control subjects). The prevalence of high IgG4 serum concentration was 4.2% among GD patients without GO and 33.33% in patients with moderate-to-severe GO. The group with GO had significantly higher median IgG4 levels (87.9 mg/dL) than the control group (41.2 mg/dL, P = 0.034) and the GD without GO group (30.75 mg/dL, P < 0.001). Patients with thyroid nodules had lower IgG4 levels than patients without thyroid nodules, but the difference was not statistically significant (35.7 [24.8; 41.53] mg/dL vs. 43 [30.1; 92.7] mg/dL, P = 0.064). IgG4 as a diagnostic tool for moderate-to-severe GO had the following parameters: area under the curve (AUC): 0.851 (P < 0.001), at the cut-off value of 49 mg/dL, negative predictive value: 100%, positive predictive value: 48%, sensitivity: 100%, specificity: 73%. There were no significant differences between the high and normal IgG4 groups in thyroid hormones, antithyroid antibodies, and ultrasound features. Serum IgG4 levels are associated with some of the clinical features of GD and can help in the diagnostic process of the disease. More research is needed to better understand the pathophysiology of IgG4 involvement in GD.
Keywords: Graves’ disease; IgG; IgG4; IgG4-related disease; Thyroid eye disease.
© 2024 Michal Olejarz et al., published by Sciendo.
Similar articles
-
Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.Thyroid. 2017 Sep;27(9):1185-1193. doi: 10.1089/thy.2017.0126. Thyroid. 2017. PMID: 28805160
-
IgG4 serum levels in Graves' orbitopathy.J Endocrinol Invest. 2024 Jul;47(7):1711-1717. doi: 10.1007/s40618-023-02265-3. Epub 2023 Dec 21. J Endocrinol Invest. 2024. PMID: 38127192
-
Study on the correlation between serum IgG4/IgG levels and the development of Graves' ophthalmopathy.Sci Rep. 2025 Jan 22;15(1):2770. doi: 10.1038/s41598-025-87126-0. Sci Rep. 2025. PMID: 39843933 Free PMC article.
-
IgG4 as a Biomarker in Graves' Orbitopathy.Mediators Inflamm. 2021 Jun 10;2021:5590471. doi: 10.1155/2021/5590471. eCollection 2021. Mediators Inflamm. 2021. PMID: 34220335 Free PMC article. Review.
-
Graves'-like orbitopathy: do not forget IgG4-related disease.J Endocrinol Invest. 2014 Dec;37(12):1233-5. doi: 10.1007/s40618-014-0171-9. Epub 2014 Sep 7. J Endocrinol Invest. 2014. PMID: 25194429 Review. No abstract available.
References
-
- Aalberse RC, van der Gaag R, van Leeuwen J (1983) Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 130:722–726. https://doi.org/10.4049/jimmunol.130.2.722
-
- Bartalena L, Kahaly GJ, Baldeschi L et al (2021) The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. Eur J Endocrinol 185:G43–G67. https://doi.org/10.1530/EJE-21-0479
-
- Bozkirli E, Bakiner OS, Ersozlu Bozkirli ED et al (2015) Serum immunoglobulin G4 levels are elevated in patients with Graves’ ophthalmopathy. Clin Endocrinol 83:962–967. https://doi.org/10.1111/cen.12671
-
- Comi S, Lanzolla G, Cosentino G et al (2023) IgG4 serum levels in Graves’ orbitopathy. J Endocrinol Invest 47, 1711–1717. https://doi.org/10.1007/s40618-023-02265-3
-
- Ebbo M, Grados A, Bernit E et al (2012) Pathologies associated with serum IgG4 elevation. Int J Rheumatol 2012:602809. https://doi.org/10.1155/2012/602809
MeSH terms
Substances
LinkOut - more resources
Full Text Sources